Cardinal Health Achieves Record Stock Price Amid Strong Financial Performance

Cardinal Health Achieves Record Stock Price Amid Strong Financial Performance

On July 6, 2026, Cardinal Health’s stock (NYSE: CAH) reached an all-time high of $241.86, reflecting the company’s robust financial performance and strategic initiatives. As of the latest trading session, the stock is priced at $237.52, with a market capitalization of approximately $56.05 billion.

Strong Financial Performance

In the third quarter of fiscal year 2026, Cardinal Health reported revenues of $60.9 billion, an 11% increase from the same period in the previous year. Non-GAAP operating earnings rose by 18% to $956 million, and non-GAAP diluted earnings per share (EPS) increased by 35% to $3.17. These results led the company to raise its fiscal year 2026 non-GAAP EPS guidance to a range of $10.70 to $10.80.

Strategic Initiatives and Market Confidence

Cardinal Health’s strategic initiatives, including the acquisition of Solaris Health, have bolstered its market position. The company’s focus on specialty drugs and branded pharmaceuticals has contributed to its strong performance. Analysts have responded positively, with UBS raising its price target for CAH to $185 from $170, citing the company’s competitive position and growth prospects.

Dividend Policy and Shareholder Returns

The company’s commitment to returning value to shareholders is evident in its dividend policy. In November 2025, Cardinal Health’s Board of Directors approved a quarterly dividend of $0.5107 per share, payable on January 15, 2026.

Conclusion

Cardinal Health’s record stock price reflects investor confidence in its financial health and strategic direction. The company’s strong earnings, strategic acquisitions, and shareholder-friendly policies position it well for sustained growth in the integrated healthcare services and products sector.